Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis |
| |
| Authors: | Paul M. Young Rania O. Salama Bing Zhu Gary Phillips John Crapper Hak-Kim Chan |
| |
| Affiliation: | 1. Department of Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, The University of Sydney, NSW, Australia,;2. Pharmaxis Pty Ltd, Frenchs Forest, Sydney, NSW, Australia, and;3. Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, NSW, Australia |
| |
| Abstract: | A series of co-engineered macrolide–mannitol particles were successfully prepared using azithromycin (AZ) as a model drug. The formulation was designed to target local inflammation and bacterial colonization, via the macrolide component, while the mannitol acted as mucolytic and taste-masking agent. The engineered particles were evaluated in terms of their physico-chemical properties and aerosol performance when delivered via a novel high-payload dry powder Orbital? inhaler device that operates via multiple inhalation manoeuvres. All formulations prepared were of suitable size for inhalation drug delivery and contained a mixture of amorphous AZ with crystalline mannitol. A co-spray dried formulation containing 200?mg of 50:50?w/w AZ: mannitol had 57.6%?±?7.6% delivery efficiency with a fine particle fraction (≤6.8?µm) of the emitted aerosol cloud being 80.4%?±?1.1%, with minimal throat deposition (5.3?±?0.9%). Subsequently, it can be concluded that the use of this device in combination with the co-engineered macrolide–mannitol therapy may provide a means of treating bronchiectasis. |
| |
| Keywords: | Bronchiectasis dry powder inhaler inhalation macrolides mucolytics orbital |
|
|
